

1 **Defining the Subtypes of Long COVID and Risk Factors for Prolonged Disease**

2 Skyler Resendez, PhD ^{1,2}, Steven H. Brown, MD ^{3,4}, H. Sebastian Ruiz ¹, Prahalad Rangan, PhD ^{1,2}, Jonathan
3 R. Nebeker, MD ^{3,5}, Diane Montella, MD ³, Peter L. Elkin, MD ^{1,2,6,7}

4 1. Department of Biomedical Informatics, Jacobs School of Medicine and Biomedical
5 Sciences, University at Buffalo

6 2. Department of Veterans Affairs, VA Western New York Healthcare System and VA Research Service

7 3. Office of Health Informatics, Department of Veterans Affairs

8 4. Department of Biomedical Informatics Vanderbilt University Medical Center

9 5. Department of Medicine, University of Utah

10 6. Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at
11 Buffalo

12 7. Faculty of Engineering, University of Southern Denmark

13

14

15

16 Word Count: 3070

17

18

19

20 Peter L. Elkin, MD, MACP, FACMI, FNYAM, FAMIA, FIAHSI

21 SUNY Distinguished Service Professor

22 UB Distinguished Professor and Chair

23 Department of Biomedical Informatics

24 Professor of Internal Medicine

25 Professor of Surgery

26 Professor of Pathology and Anatomical Sciences

27 Professor of Psychiatry

28 Professor of Orthopedics

29 President, Faculty Council

30 Jacobs School of Medicine and Biomedical Sciences

31 University at Buffalo

32 State University of New York

33 <http://medicine.buffalo.edu/departments/biomedical-informatics.html>

34 77 Goodell Street, Buffalo, NY 14203

35 507 358-1341

36 **Abstract**

37

38 **Importance:** There have been over 759 million confirmed cases of COVID-19 worldwide. A significant
39 portion of these infections will lead to long COVID and its attendant morbidities and costs.

40 **Objective:** To empirically derive a long COVID case definition consisting of significantly increased signs,
41 symptoms, and diagnoses to support clinical, public health, research, and policy initiatives related to the
42 pandemic.

43 **Design:** Case-Crossover Population-based study.

44 **Setting:** Veterans Affairs (VA) medical centers across the United States between January 1, 2020 and
45 August 18, 2022.

46 **Participants:** 367,148 individuals with positive COVID-19 tests and preexisting ICD-10-CM codes
47 recorded in the VA electronic health record were enrolled.

48 **Trigger:** SARS-CoV-2 infection documented by positive laboratory test.

49 **Case Window:** One to seven months following positive COVID testing.

50 **Main Outcomes and Measures:** We defined signs, symptoms, and diagnoses as being associated with
51 long COVID if they had a novel case frequency of $\geq 1:1000$ and they were significantly increased in our
52 entire cohort after a positive COVID test when compared to case frequencies before COVID testing. We
53 present odds ratios with confidence intervals for long COVID signs, symptoms, and diagnoses, organized
54 by ICD-10-CM functional groups and medical specialty. We used our definition to assess long COVID risk
55 based upon a patient's demographics, Elixhauser score, vaccination status, and COVID disease severity.

56 **Results:** We developed a long COVID definition consisting of 323 ICD-10-CM diagnosis codes grouped
57 into 143 ICD-10-CM functional groups that were significantly increased in our 367,148 patient post-
58 COVID population. We define seventeen medical-specialty long COVID subtypes such as cardiology long
59 COVID. COVID-19 positive patients developed signs, symptoms, or diagnoses included in our long COVID
60 definition at a proportion of at least 59.7% (based on all COVID positive patients). Patients with more
61 severe cases of COVID-19 and multiple comorbidities were more likely to develop long COVID.

62 **Conclusions and Relevance:** An actionable, empirical definition for long COVID can help clinicians screen
63 for and diagnose long COVID, allowing identified patients to be admitted into appropriate monitoring
64 and treatment programs. An actionable long COVID definition can also support public health, research
65 and policy initiatives. COVID patients with low oxygen saturation levels or multiple co-morbidities should
66 be preferentially watched for the development of long COVID.

67

68 **Long COVID – Current Knowledge Base and Need**

69 Numerous symptoms are cited as long-term sequela of COVID-19. “The symptoms may affect a number
70 of organ systems, occur in diverse patterns, and frequently get worse after physical or mental activity.”¹
71 A 2020 study found that the most common long-term symptoms were fatigue, dyspnea, joint pain, and
72 chest pain.² Others reported gastrointestinal tract disorders correlated with gut microbiome shifts after
73 COVID-19 infection.^{3,4} Cognitive dysfunction, often referred to as brain fog, is a commonly reported
74 long-term symptom.⁵ Cognitive dysfunction is particularly concerning given evidence that COVID-19 can
75 alter brain structure.⁶ The most common self-reported symptoms documented via a smartphone app
76 were fatigue, headache, dyspnea, and anosmia.^{7,8}

77 Concerningly high long COVID frequencies have been reported. A cohort study from the Netherlands
78 found that approximately one in eight COVID-19 patients developed long-term somatic symptoms.⁹
79 Another study showed that approximately thirty percent of their cohort reported persistent symptoms,
80 with many experiencing worse health-related quality of life (HRQoL) compared with baseline and
81 negative impacts on at least one activity of daily living.¹⁰

82 Long COVID’s impacts extend beyond individual morbidity to include healthcare system and economic
83 consequences. Cutler et. al. noted long COVID resulting in reduced workforce participation (e.g., 44%
84 out of the work force), direct earning losses and worker shortages in service jobs.¹¹ A recent analysis of
85 New York State disability claims trends described in the New York Times found that “71 percent of
86 claimants with long COVID needed continuing medical treatment or were unable to work for six months
87 or more” and opined that long COVID has exacerbated the current US labor shortage.^{12,13}

88 The widespread occurrence of lingering ailments and their impacts on individuals and society make clear
89 the need for a long COVID definition. U.S. public health officials note that we must balance our need for
90 an accurate long COVID definition that includes all afflicted individuals with against our need for interim
91 long COVID definitions to expedite immediate action and mobilization.¹⁴ In particular, a working
92 definition of long COVID based on routinely collected coded data could support the identification of at
93 risk or undiagnosed patients for monitoring, referral, or therapeutic interventions. In the current study
94 we empirically derive an actionable broad-based long COVID definition to support current clinical, public
95 health, research and policy initiatives related to the pandemic.


96

97 **Methods**

98 **Overview**

99 We enrolled Veterans who had laboratory confirmed positive COVID 19 tests. We examined Veterans’
100 electronic health records for novel International Classification of Diseases, 10th Revision, Clinical
101 Modification (ICD-10-CM) codes between one and seven months after a positive COVID-19 test. We
102 grouped codes with a novel frequency of 1/1000 or greater by diagnosis type creating ICD-10-CM
103 functional groups and performed Chi-square testing with Bonferroni correction to compare diagnosis
104 frequencies before and after a positive COVID test. We defined ICD-10-CM functional groups that
105 significantly increased in frequency as “upregulated” (see Figure 1). We then manually aggregated
106 upregulated ICD-10-CM functional groups into medical specialties to organize our empiric definition of
107 long COVID.

108



109

110 **Figure 1.** Workflow and data curation in the sequence utilized to generate our long COVID definition. T_0 :
111 Date of positive COVID-19 test. M: Months.

112 Population Definition and Data Extraction


113 We enrolled patients with laboratory confirmed positive COVID-19 studies and followed them for
114 thirteen months (Six months before the COVID 19 test result and seven months after COVID) to create a
115 long COVID definition. We utilized the electronic health records (EHR) of all patients that tested positive
116 for COVID-19 at Veterans Affairs (VA) medical facilities nationally between January 1, 2020 and August
117 18, 2022. 2,377,720 patients were tested for COVID-19 during this time period.

118 We applied structured query language (SQL) queries to VA Informatics and Computing Infrastructure
119 (VINCI), Corporate Data Warehouse (CDW) data tables¹⁵ to generate two diagnosis files for analysis. The
120 first file (“before”) contains a row of retrospectively collected information for each patient and each
121 ICD-10-CM diagnosis assigned to them in the six-month control window prior to their COVID-19 test. The
122 row includes the ICD-10-CM code and its description, a unique patient identifier, the COVID-19 test date,
123 and the calculated number of months between ICD-10-CM code entry and COVID-19 testing. This
124 “before” file contained 14,980,288 observations across 426,970 patients.

125 We followed the patients for seven months. The second file (“after”) was created seven months after
126 the last patient was enrolled. The after file contained ICD-10-CM codes assigned during the seven
127 months following COVID-19 testing and similar related information as the “before” file. This “after” file
128 contained 15,493,587 observations across 389,677 patients.

129 We limited analysis to the 367,148 patients that appeared in both the “before” and “after” files to
130 ensure that we had a diagnostic history for each patient and eliminated acute findings by removing all
131 ICD-10-CM codes documented less than a month after the positive COVID test (Figure 1). We used the
132 date of the first positive COVID test for patients with multiple positive tests. Multiple repeating ICD-10-
133 CM codes for a single patient were counted once. We wrote R and python programs to remove all data
134 concerning patients who tested negative for COVID-19, ICD-10-CM codes that were documented less
135 than a month after the positive COVID-19 test, and patients who were not present in both the “before”
136 and “after” files. The methodology used to generate the patient cohort is depicted in Figure 2.

137



138

139 **Figure 2. Recruitment Flowchart for the Study**

140 We collected additional data to examine the association of demographics, comorbidities, vaccination
141 status, and COVID-19 case severity with the incidence of long COVID. Demographic data collected
142 included age, sex, race, and ethnicity. Comorbidities were evaluated using 2-year Elixhauser Comorbidity
143 Indices Scores. Vaccinated patients were defined as having at least one COVID-19 vaccine dose recorded
144 at least two weeks and no more than nine months before their positive COVID-19 test. We defined two
145 classes of severe COVID-19 based on minimum recorded oxygen saturation. The first class, severe
146 COVID-19, was defined by a minimum oxygen saturation of <94%.¹⁶ The second class, severe COVID-19
147 with severe desaturation, was defined by a minimum oxygen saturation of < 88%.¹⁷

148

149 **Data Analysis**

150 We chose six month “before” and “after” COVID test control and case windows to allow patients to
151 serve as their own controls. The six month “after” case window began one month after the positive
152 COVID test. We defined “novel” ICD-10-CM codes as those that appeared in a patient’s “after” file but
153 not in the “before” file. We calculated the frequency of each novel ICD-10-CM code as the percentage of
154 the study cohort assigned the code. We excluded novel codes with a frequency of < 1:1000 from further
155 analysis. We defined codes as upregulated when the frequency of that code in the after file was
156 significantly increased as compared to the frequency in the before file, if it had a Chi-Square with a
157 Bonferroni corrected p-value<0.00006. All resulting codes were grouped for additional analysis and
158 organization (see ICD-10-CM Functional and Medical Specialty Groupings subsection of Methods).

159 We also defined ICD-10-CM functional groups as “upregulated” if they were statistically more frequent
160 post COVID by Chi Square analysis with Bonferroni correction with a p<0.00006. We limited the long
161 COVID ICD-10-CM code functional groups to those that were significantly increased in frequency. We
162 used “before” and “after” frequencies to calculate odds ratios and confidence intervals for each novel
163 ICD-10-CM functional group. We calculated odds ratios from frequency data.

164 We analyzed potential risk factors including vaccination status and COVID-19 severity for long COVID by
165 creating 2x2 tables and applying Pearson Chi-Square testing. We applied a similar approach to the
166 analysis of demographic factors. We used R version 4.1.2 and R-Studio to perform the statistical analysis.

167

168 **ICD-10-CM Functional and Medical Specialty Groupings**

169 We grouped ICD10 CM codes in three steps. We first combined ICD-10-CM codes that had the same
170 initial three characters. We then grouped ICD-10-CM codes with different initial characters if the
171 diagnoses were functionally similar to create our ICD-10-CM functional groups. For example, we
172 grouped I47.1 (supraventricular tachycardia), I47.2 (ventricular tachycardia), and R00.0 (tachycardia,
173 unspecified) together as tachycardia. Finally, we manually curated each of these ICD-10-CM functional
174 groups into medical specialties for organizational purposes.

175 **Long COVID Definition**

176 We included in our long COVID definition each ICD-10-CM code with an incidence over six months ($T_0 +$
177 $1M - T_0 + 7M$) > 1:1000 and a significant overall frequency increase. Long COVID patients were defined as
178 having any of the 323 upregulated ICD-10-CM codes between two and seven months after their positive
179 COVID-19 diagnosis, but not in their pre-COVID diagnoses.

180 **Risk Factors for Long COVID**

181 The multivariate regression models were done for each risk factor one including Age, Gender, Race,
182 Ethnicity, 2-year Elixhauser score, a second with Age, Gender, Race, Ethnicity, 2-year Elixhauser score,
183 O2Sat <94%, and a third with Age, Gender, Race, Ethnicity, 2-year Elixhauser score, COVID Vaccination
184 status. We present the univariate rates as well as the results of the regression analysis using R4.1.2 and
185 R Studio.

186 **Results**

187 **Long COVID Definition**

188 We extracted ICD-10-CM diagnosis codes assigned to 367,148 patients who underwent a positive COVID
 189 test at VA. Patients with one or more novel COVID related diagnoses numbered 268,320. The remaining
 190 98,828 patients had no novel long COVID ICD-10-CM diagnoses in their post-COVID period when
 191 compared to their pre-COVID period. Table 1 contains the demographic characteristics of the study
 192 cohort. Males were significantly older than the females on average, 60.29 (95% CI: 95% CI: 60.24 –
 193 60.35) versus 47.85 (95% CI: 47.73 – 47.97), respectively.

	Non-Long COVID Patients (98,828)	Long COVID Patient (268,320)	P Value
Age (Mean/Conf. int.)	52.14 (52.03 – 52.24)	60.85 (60.79 – 60.91)	-
Elixhauser Score (Mean/Conf. int.)	3.03 (2.99 – 3.07)	7.05 (7.01 – 7.09)	-
Sex			
Male	75,418 (76.31%)	234,720 (87.48%)	< 0.00001
Female	16,854 (17.05%)	31,651 (11.80%)	< 0.00001
Not Listed	6,556 (6.63%)	1,949 (0.73%)	< 0.00001
Ethnicity			
Hispanic or Latino	10,147 (10.27%)	26,171 (9.75%)	< 0.00001
Not Hispanic or Latino	71,595 (72.44%)	227,404 (84.75%)	< 0.00001
Not Listed	17,086 (17.29%)	14,745 (5.50%)	< 0.00001
Race			
American Indian or Alaska Native	743 (0.75%)	2,243 (0.84%)	0.01182
Asian	1,420 (1.44%)	2,973 (1.11%)	< 0.00001
Black or African American	20,779 (21.03%)	65,218 (24.31%)	< 0.00001
Native Hawaiian/Other Pacific Islander	905 (0.92%)	2,522 (0.94%)	0.49900
White	55,359 (56.02%)	173,169 (64.54%)	< 0.00001
Not Listed	19,622 (19.85%)	22,195 (8.27%)	< 0.00001

194

195 **Table 1.** Demographic data and two-year Elixhauser scores for long COVID patients and non-long COVID
 196 patients

197 We developed a definition of long COVID consisting of 323 ICD-10-CM diagnosis codes grouped into 143
 198 ICD-10-CM functional groups that were significantly increased in our 367,148 patient post-COVID
 199 population. We define seventeen medical specialty long COVID subtypes including cardiology long
 200 COVID, neurology long COVID, and pulmonary long COVID. Table 2 shows the ICD-10-CM functional
 201 groups and medical specialties. Within each field, the ICD-10-CM code groups are sorted in descending
 202 order by their Odds Ratios.

Functional Group Description	Medical Specialty	ICD-10-CM Codes	Novel Count	Odds Ratio
Hypotension	Cardiology	I95.1, I95.89, I95.9	7865	1.271538

Heart Failure Diastolic Dysfunction	Cardiology	I11.0	4594	1.26876
Cardiac Arrhythmia	Cardiology	I47.1, I48.0, I48.19, I48.20, I48.21, I48.3, I48.91, I48.92, I49.3, R00.0, R00.2	35648	1.223517
Cardiovascular Disease	Cardiology	I21.A1, I24.8, I25.10, I25.2, I25.5, I42.8, I42.9, I50.20, I50.22, I50.23, I50.30, I50.32, I50.33, I50.42, I50.9, I71.40	45157	1.206416
Valve Stenosis/Insufficiency	Cardiology	I27.82, I34.0, I35.0	3916	1.171221
Peripheral Vascular Disease	Cardiology	I73.9	4862	1.105507
Hyperlipidemia	Cardiology	E78.2, E78.5	54913	1.070793
Hypertension	Cardiology	I10	39677	1.046517
Gingival Recession	Dentistry	K06.010, K06.020	2497	1.256852
Gingivitis	Dentistry	K03.0, K05.00, K05.10, K05.321, K05.322, K06.1	7818	1.235098
Dental Caries	Dentistry	K02.3, K02.51, K02.52, K02.62, K02.7	19887	1.154138
Pressure ulcer	Dermatology	L89.152, L89.153, L89.159	1639	2.3395
Nonscarring Hair Loss	Dermatology	L65.9	441	1.853409
Melanocytic Nevi	Dermatology	D22.9	1886	1.195428
Nail Dystrophy	Dermatology	L60.3	5209	1.152928
Xerosis Cutis	Dermatology	L85.3	4048	1.133044
Fatigue	Endocrinology	G93.3	542	10.18039
Malnutrition	Endocrinology	E43, E44.0, E46, E63.9, R63.8, R64	6372	1.856287
Adult Failure to Thrive	Endocrinology	R62.7	1827	1.578271
Phosphorus Metabolism Disorder	Endocrinology	E83.39	1306	1.297077
Abnormal Weight Loss	Endocrinology	R63.4	4439	1.16755
Osteoporosis	Endocrinology	M81.0	1442	1.120668
Prediabetes	Endocrinology	R73.03	6402	1.105807
Type 2 Diabetes Mellitus	Endocrinology	E11.22, E11.3291, E11.36, E11.40, E11.42, E11.51, E11.649, E11.65, E11.9	49454	1.104288
Hypothyroidism	Endocrinology	E03.9	7059	1.050629
Obesity	Endocrinology	E66.9	19041	1.038481
Ileus	Gastroenterology	K56.7	693	1.585583

Enterocolitis	Gastroenterology	A04.72	760	1.568205
Elevation of Liver Transaminase Levels	Gastroenterology	R74.01	2117	1.515881
Polyp of Stomach and Duodenum	Gastroenterology	K31.7	718	1.339522
Ascites	Gastroenterology	R18.8	795	1.332139
Esophagitis	Gastroenterology	K08.499, K20.80, K20.90, K22.89	3013	1.317627
Portal Hypertension	Gastroenterology	K76.6	671	1.291358
Dysphagia	Gastroenterology	R13.10, R13.11, R13.12, R13.13	13011	1.274248
Constipation	Gastroenterology	K59.00, K59.03, K59.09	13376	1.224596
Diseases of Stomach and Duodenum	Gastroenterology	K31.89	1394	1.193473
Gastritis	Gastroenterology	K29.50, K29.70	2963	1.191019
Gastrointestinal Hemorrhage	Gastroenterology	K92.2	2320	1.186902
Diverticulosis	Gastroenterology	K57.30	5522	1.168767
Melena	Gastroenterology	K92.1	2334	1.143609
Cirrhosis of Liver	Gastroenterology	K74.60	1683	1.13734
Gastro-Esophageal Reflux Disease	Gastroenterology	K21.00, K21.9	31020	1.086091
Fatty Liver	Gastroenterology	K76.0	4912	1.081379
Homelessness	General Internal Medicine	Z59.00, Z59.01, Z59.02, Z59.811, Z59.812, Z59.819, Z59.89	11511	1.456793
Vitamin Deficiency	General Internal Medicine	E53.8, E55.9	21619	1.105953
Pulmonary Embolism without Acute Cor Pulmonale	Hematology	I26.99	2670	1.804971
MGUS	Hematology	E88.09, R77.8	1273	1.542297
Acute Embolism and Thrombosis	Hematology	I82.401, I82.402, I82.409, I82.890	2510	1.42562
Pancytopenia	Hematology	D61.818	939	1.291209
Thrombocytopenia	Hematology	D69.59, D69.6	3876	1.260737
Abnormal Coagulation Profile	Hematology	R79.1	826	1.250246
Anemia	Hematology	D50.0, D50.9, D53.9, D62, D63.0, D63.1, D63.8, D64.89, D64.9	30750	1.242379
Abnormal White Blood Cell Count	Hematology	D72.829	3528	1.167524

Infectious Sequelae	Infectious Diseases	B94.8	606	23.42175
Viral Pneumonia	Infectious Diseases	J12.89	1604	2.478623
Influenza	Infectious Diseases	J09.X2	547	2.193782
Thrush	Infectious Diseases	B37.0	537	1.844434
Sepsis	Infectious Diseases	A41.89, A41.9, R65.20, R65.21	6816	1.608247
Pseudomonas	Infectious Diseases	B96.5	682	1.595698
Enterococcus	Infectious Diseases	B95.2	884	1.594505
Bacterial Pneumonia	Infectious Diseases	J15.9	2862	1.54475
MRSA	Infectious Diseases	B95.62, Z22.322	1316	1.488166
Bacteremia	Infectious Diseases	R78.81	2139	1.377602
Klebsiella	Infectious Diseases	B96.1	728	1.376463
MSSA	Infectious Diseases	B95.61, B95.7	1015	1.341265
Proteus	Infectious Diseases	B96.4	511	1.336283
E. Coli	Infectious Diseases	B96.20	1077	1.319389
Osteomyelitis	Infectious Diseases	M86.9	1121	1.224393
Urinary Tract Infection	Infectious Diseases	N39.0, T83.511A	8553	1.161612
Drug Toxicity	Nephrology	T38.0X5A, T45.1X5A	1073	1.686641
Dehydration	Nephrology	E86.1	959	1.293327
Acute Kidney Failure	Nephrology	N17.0, N17.8, N17.9	11392	1.290399
Disorders of Fluid, Electrolyte and Acid-Base Balance	Nephrology	E83.42, E83.52, E87.0, E87.1, E87.2, E87.20, E87.3, E87.4, E87.5, E87.6, E87.70, E87.8	25885	1.276923
Chronic Kidney Disease	Nephrology	I12.0, I12.9, I13.0, I13.2, N18.2, N18.30, N18.31, N18.32, N18.4, N18.6, N18.9, N28.89, Z99.2	35590	1.258035
Edema	Nephrology	R60.0, R60.9	11683	1.116561
Encephalopathy	Neurology	G92.8, G93.40, G93.41, G93.49	4476	1.705173

Delirium	Neurology	F05	1414	1.639297
Lower Back Pain	Neurology	M54.50	24694	1.578581
Muscle Weakness	Neurology	M62.81	9362	1.277051
Need for Assistance with Personal Care	Neurology	Z74.1	3287	1.276263
Weakness	Neurology	R53.1, R54	15912	1.258534
Cognitive Impairment	Neurology	R41.0, R41.81, R41.82, R41.841, R41.89, R41.9	10045	1.241561
Wheelchair	Neurology	Z99.3	654	1.234073
Seizure Disorder	Neurology	G40.909	1155	1.205124
Dementia	Neurology	F01.50, F02.80, F03.90, G30.9, G31.84	10406	1.204819
Falls	Neurology	R29.6	1879	1.199129
Difficulty in Walking	Neurology	R26.2, R26.89, R26.9, Z74.09	22449	1.171356
Falling	Neurology	Z91.81	3164	1.157633
Tinnitus	Neurology	H93.13	8889	1.135359
Cerebrovascular Disease	Neurology	I63.9, I69.351, I69.354	4200	1.119552
Neuropathy	Neurology	G62.9, G89.18, G89.29, G89.3, G89.4	23681	1.118604
Cervicalgia	Neurology	M54.2	13691	1.052616
Malignant Neoplasm of Liver	Oncology	C78.7	420	1.704389
Malignant Neoplasm of Lung	Oncology	C34.90	657	1.350535
Malignant Neoplasm of Bone	Oncology	C79.51	622	1.314306
Solitary Pulmonary Nodule	Oncology	R91.1	5557	1.116382
Conjunctivitis	Ophthalmology	H10.45	2645	1.180325
Retinopathy	Ophthalmology	H35.372, H35.373	2413	1.173309
Dry Eye Syndrome	Ophthalmology	H04.123	19581	1.164934
Presbyopia	Ophthalmology	H52.4	36752	1.154351
Myopia	Ophthalmology	H52.13	8012	1.151422
Vitreous Degeneration	Ophthalmology	H43.813	3085	1.142235
Astigmatism	Ophthalmology	H52.203, H52.223	13737	1.140477
Unspecified Disorder of Refraction	Ophthalmology	H52.7	7093	1.126198
Open Angle with Borderline Findings	Ophthalmology	H40.013	6278	1.121644
Cataracts	Ophthalmology	H25.012, H25.11, H25.12, H25.13, H25.811, H25.812, H25.813, H26.9	42904	1.119152
Hypermetropia	Ophthalmology	H52.03	7317	1.110326

Epistaxis	Otolaryngology	R04.0	1342	1.235389
Dysphonia	Otolaryngology	R49.0	1368	1.182724
Impacted Cerumen	Otolaryngology	H61.23	3780	1.121918
Sensorineural Hearing Loss	Otolaryngology	H90.3, H90.A22	17093	1.1138
Restlessness and Agitation	Psychiatry / Psychology	R45.1	893	1.279866
Mental Disorder	Psychiatry / Psychology	F09, F32.A, F41.1, F41.9, F43.12	48256	1.135075
Malaise	Psychiatry / Psychology	R53.81	2251	1.132321
Problems Related to Psychosocial Circumstances	Psychiatry / Psychology	Z65.8, Z65.9	23892	1.102123
Acute Respiratory Distress Syndrome	Pulmonary	J80	688	5.299347
Dependence on Ventilator	Pulmonary	Z99.11	427	3.146519
Chronic Cough	Pulmonary	R05.3	2113	2.026076
Respiratory Failure	Pulmonary	J96.00, J96.01, J96.02, J96.10, J96.11, J96.20, J96.21, J96.22, J96.90, J96.91	14882	1.997749
Dependence on Supplemental Oxygen	Pulmonary	R09.02, Z99.81	7792	1.715279
Interstitial Pulmonary Disease	Pulmonary	J84.9	685	1.536233
Pulmonary Fibrosis	Pulmonary	J84.10	1232	1.527598
Pleural Effusion	Pulmonary	J90, J91.8	2990	1.4413
Abnormalities of Breathing	Pulmonary	R06.89	1107	1.338466
Pneumonia	Pulmonary	J16.8, J17, J18.8, J18.9, J69.0	8181	1.315208
Acute Pulmonary Edema	Pulmonary	J81.0	624	1.295683
Pulmonary Hypertension	Pulmonary	I27.20	1782	1.282603
Respiratory Disorders	Pulmonary	J98.4, J98.8, J98.9	3711	1.281901
Emphysema	Pulmonary	J43.9	1700	1.229811
Dyspnea	Pulmonary	R06.00, R06.02, R06.03, R06.09	27926	1.206525
Atelectasis	Pulmonary	J98.11	1766	1.206262
Diaphragmatic Hernia	Pulmonary	K44.9	2952	1.169074
Chronic Obstructive Pulmonary Disease	Pulmonary	J44.0, J44.9	12639	1.131736
Asthma	Pulmonary	J45.909	4126	1.093696
Sleep Disorders	Pulmonary	G47.00, G47.33	41147	1.090759
Osteoarthritis	Rheumatology	M17.0	4546	1.090886
Gout	Rheumatology	M10.9	5997	1.057874
Uropathy	Urology	N13.9	597	1.256139
Retention of Urine	Urology	R33.8, R33.9	6269	1.251816

Obstructive and Reflux Uropathy	Urology	N13.8	1385	1.204741
Urinary Incontinence	Urology	N31.9, R32	3843	1.153016
Benign Prostatic Hyperplasia	Urology	N40.0, N40.1	24210	1.128437
Frequency of Micturition	Urology	R35.0	3032	1.106673


203

204

205 **Table 2.** Long COVID definition results by ICD-10-CM Functional group description and medical specialty.

206 Figures 3 and 4 show the signs, symptoms, and diagnoses with significantly increased relative risks in the


207 post-COVID period with their respective confidence intervals sorted by medical specialty.



208


209

Figure 3. Odds ratios < 3 for long COVID ICD-10-CM functional groups by medical specialty subtype.



210

211 **Figure 4.** Odds ratios > 3 for long COVID ICD-10-CM functional groups by medical specialty subtype.




212

213 **Figure 5.** Case counts by medical specialty

214 Case counts were greatest for the specialties of Cardiology (196,632, Neurology (159,358),
 215 Ophthalmology (149,817) and Pulmonary (138,470). The lowest case counts were for Oncology (7,256),
 216 Rheumatology (10,543) and Dermatology (13,233).

217 COVID-19 test positive patients were assigned novel signs, symptoms, or diagnoses included in our
 218 definition of long COVID at a rate of between 59.7% (percentage based on COVID positive patients
 219 tested at the VA) and 76.6% (percentage based on all COVID positive patients with diagnostic history
 220 and follow up diagnoses one to seven months after test).

221 Most long COVID patients were documented with at least one ICD-10-CM code found in our long COVID
 222 definition within three months of their positive COVID-19 test. The percentage of patients documented
 223 with their first long COVID ICD-10-CM code decreases with each subsequent month (See Figure 6).



224
 225 **Figure 6.** Percentage of prospective post COVID-19 diagnosis (Months 1-7) that each long COVID patient
 226 had their first long COVID ICD-10-CM code documented. Month 0-1 ICD-10-CM codes were not included
 227 as they included acute symptoms.

228
 229 **Risk Factors for Long COVID**

230 We presented in Table 1 a comparison of demographic characteristics and Elixhauser comorbidity scores
 231 of long COVID patients and non-long COVID patients. The long COVID cohort was older with more
 232 comorbidities. The long COVID cohort also had higher percentages of White and Black individuals and
 233 non-Hispanic and non- Latino ethnicities. Patients with a 2-year Elixhauser score of greater than 21 had a
 234 much higher proportion developing long COVID ($p < 0.001$, Pearson Chi-Square) (See Table 3).

2 Year Elixhauser Score	No Long COVID Count	Long COVID Count	Percent Long COVID (95% CI)
0-21	96,055	242,108	71.60% (71.44% - 71.75%)
22-42	2,454	22,716	90.25% (89.88% - 90.61%)
43-63	308	3,317	91.50% (90.55% - 92.36%)
64-84	11	179	94.21% (89.93% - 96.77%)

235 **Table 3.** Proportion of patients that developed long COVID comparing different 2-year Elixhauser score
236 ranges.

237 Our data did not indicate that vaccination was protective against the development of long COVID.
238 However, vaccination resulted in significantly lower rates of novel ARDS in the post-covid period (13.2%
239 CI: 10.4%-16.9%) as compared with the unvaccinated population (19.6% CI: 18.1% - 21.2), $p < 0.001$.

240 Patients with minimum O2 saturations constituting severe COVID and severe COVID with severe
241 desaturation were significantly more likely to develop long COVID (both had p -values < 0.001 , Pearson
242 Chi-Square) (See Table 4).

Severe COVID	No Long COVID Count	Long COVID Count	Percent Long COVID (95% CI)
Low O2 (NIH Definition*)	3,903	29,411	88.28 % (87.93% - 88.63%)
No Low O2 (NIH Definition*)	94,925	238,909	71.57% (71.41% - 71.72%)
Low O2 (Severe Desaturation**)	637	5,566	89.73% (88.95% - 90.46%)
No Low O2 (Severe Desaturation**)	98,191	262,754	72.80% (72.65% - 72.94%)
* Min(O2 Sat) < 94% ** Min(O2 Sat) < 88%			

243 **Table 4.** Low oxygen saturations and the proportion of patients that developed long COVID.

244 The multivariate regression models all confirmed that COVID patients during the Omicron variant
245 predominant period were at slightly higher risk of developing Long COVID at p -value < 0.001 .

246 Discussion

247 Numerous reports document specialty-specific signs, symptoms and diagnoses correlated with long
248 COVID. We present a novel analysis based on a large national data set and the full multispecialty
249 breadth of ICD-10-CM diagnosis codes to create an overall holistic long COVID definition that confirms
250 and extends previous reports.

251 We allowed patients to be their own controls and used the entire cohort before and after COVID-19
252 infection to determine the relative risk of signs, symptoms, and disorders. This ensured that the signal
253 was both novel and upregulated. We found COVID-19 positive patients developed signs, symptoms, or
254 diagnoses included in our long COVID definition at a proportion of between 59.7% (percentage based on
255 COVID positive patients tested at the VA) and 76.6% (percentage based on all COVID positive patients
256 with diagnostic history and follow up diagnoses one to seven months after test). More than three-
257 fourths of long COVID patients met our long COVID definition within four months of their positive
258 COVID-19 test.

259 We found long COVID frequency differences based on race and ethnicity. These differences may be
260 related to socioeconomic status, which is directly correlated with the presence of comorbidities.¹⁸⁻²⁰ The
261 long COVID cohort was eight years older with more comorbidities (two-year Elixhauser score 7.97 in the
262 long Covid patients vs 4.21 in the non-long Covid patients). In our cohort, the males were significantly
263 older than the females on average, 60.29 (95% CI: 95% CI: 60.24 – 60.35) versus 47.85 (95% CI: 47.73 –
264 47.97), respectively. We found that long COVID frequency was increased in female patients, the more
265 severely ill, and patients who had a more severe bout of COVID as judged by their minimum oxygen
266 saturation.

267 We found 143 upregulated diagnostic groups, with odds ratios as high as 23. We also found seventeen
268 upregulated medical specialty groupings containing between three and twenty-one signs, symptoms, or
269 diagnoses. This provides strong evidence for a broad definition of long COVID.

270 Carfi et al. found that most common long-term symptoms were fatigue, dyspnea, joint pain, and chest
271 pain.² Each except joint pain is represented in our long COVID definition. However, joint pain may be
272 related to findings in our definition such as difficulty walking and an overall decrease in mobility. COVID-
273 19 is known to cause lung abnormalities, especially in cases with pneumonia.²¹ We found that the
274 likelihood of developing pneumonia after COVID-19 infection is significantly upregulated, potentially
275 interconnected with the numerous findings in our Pulmonary long COVID definition. Autopsy evaluation
276 of COVID-19 victims' lung tissue demonstrated diffuse alveolar damage with perivascular T-cell
277 infiltration and severe endothelial injury.²² Long COVID patients have been found to have abnormal
278 ¹²⁹Xe MRI gas exchange and CT vascular density measurements, which we postulate could be related to
279 the pulmonary fibrosis (J84.10) or emphysema (J43.9) diagnoses identified in our definition.²³

280 Our definition shows that the long-term effects of COVID-19 are associated with damage to numerous
281 body systems including the kidneys, heart, eyes, and nervous system. Our results are corroborated by
282 other studies. Cognitive dysfunction (brain fog) is often associated with long COVID and can be difficult
283 to diagnose and treat.⁵ COVID-19 infection is far more likely to cause cardiac complications than
284 vaccination.²⁴ The gastrointestinal codes we observed reflect previous literature²⁵ and may relate to
285 reported alterations to the gastrointestinal tract after COVID-19.^{3,4} Finally, previous studies have noted
286 that COVID can alter ocular physiology, supporting our ophthalmology related findings.²⁶

287 Patients with more severe cases of COVID 19, as manifest by low oxygen saturations, should be watched
288 carefully for the development of long COVID as they were significantly more likely to develop long
289 COVID. Sicker patients with higher 2-year Elixhauser scores were significantly more likely to develop long
290 COVID. Patients with multiple comorbidities should be made aware of this risk and participate in active
291 surveillance for the development of signs and symptoms of long COVID.

292 The American Medical Association (AMA) notes there are three categories of long COVID patients: Those
293 who do not recover completely and have ongoing symptoms; those with symptoms related to chronic
294 hospitalization; and those who develop new symptoms after recovery.²⁷ In our study, we did not
295 differentiate by these subtypes and instead leave that to future research. It is possible that some of
296 these signs and symptoms may have occurred during the first month and may be the persistent subtype.
297 It is possible that some of the upregulated codes may be found with other serious illnesses, though only
298 9.1% of our cohort had severe COVID based on oxygen saturation <94%. We are not able to distinguish
299 conditions that represent acceleration of pre-existing disease from those that represent de novo COVID-
300 related conditions. For example, is the increased incidence of Non-ST elevation (NSTEMI) myocardial
301 infarction (I21.4) related to the general stress of acute illness impacting preexisting coronary artery
302 disease or to an underlying de novo long COVID related condition? Better understanding will require
303 additional research. In any event, whether causal or associative, de novo disease or exacerbation of
304 chronic disease, new or persistent clinical problems require assessment, treatment, and monitoring.

305 Limitations include that the cohort study population is 84% male, reflective of the overall VA patient
306 population which is between 87% and 95% male (depending upon data source and whether gender has
307 been self-reported).^{28,29} Additionally, the male Veteran population who use the VA healthcare system is
308 older than the population of female Veterans who use VA. Our study did not include home testing for

309 Covid-19 that went unreported to the VA healthcare system. Patients who tested positive during the
310 omicron dominant time period were slightly more likely to develop Long COVID when compared to the
311 earlier strains (76% vs 72%, $p < 0.001$). The reality of emerging viral variants emphasizes the need for a
312 well-defined and well-maintained definition of long COVID over time and with variant-specific
313 derivation. The study was not powered to show independence of the individual risk factors for long
314 COVID.

315 In this case-crossover study, we hope that our empirically defined long COVID definition will lead to
316 more consistent identification of long COVID and its medical specialty subtypes and support of a variety
317 of COVID related initiatives. Our definition is actionable as individuals who have multiple co-morbidities
318 and more severe bouts of COVID should be followed more closely for the development of long covid
319 signs or symptoms. Our definition can also inform screening questions for high-risk patients. For
320 example, helping clinicians identify patients with enhanced long COVID risk who may benefit from
321 monitoring programs or patients with previously undiagnosed long COVID for whom it may be
322 appropriate to create a referral to a long COVID clinic. We also anticipate that our long COVID definition
323 may support through standardization of future subspecialty specific long COVID research.

324 Future research should look at health outcomes for each long COVID medical specialty subtypes to
325 identify those at greatest risk of developing severe morbidity. Predictive analytics should be employed
326 to help refer these individuals earlier to monitoring and treatment programs.

327 As of March 5th, 2023, there have been 759 million confirmed cases of COVID-19 worldwide.³⁰ Case
328 counts are ever increasing. As Dr. Levine notes, immediately useful long COVID definitions are needed as
329 are ultimately more fully inclusive definitions.¹⁴ We offer our long COVID definition as a public health
330 contribution to our pandemic response.

331

332 **Acknowledgements**

333 This work has been supported in part by grants from NIH NLM T15LM012495, R25LM014213, NIAAA
334 R21AA026954, R33AA0226954 and NCATS UL1TR001412. This study was funded in part by the
335 Department of Veterans Affairs.

336

337 **References**

- 338 1. Phillips S, Williams MA. Confronting Our Next National Health Disaster — Long-Haul Covid. *New*
339 *England Journal of Medicine* 2021;385(7):577–9.
- 340 2. Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*
341 2020;324(6):603.
- 342 3. Ng SC, Tilg H. COVID-19 and the gastrointestinal tract: more than meets the eye. *Gut*
343 2020;69(6):973–4.
- 344 4. Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome.
345 *Translational Research* 2020;226:57–69.

- 346 5. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7
347 months of symptoms and their impact. *EClinicalMedicine* 2021;38:101019.
- 348 6. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain
349 structure in UK Biobank. *Nature* 2022;604(7907):697–707.
- 350 7. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict
351 potential COVID-19. *Nat Med* 2020;26(7):1037–40.
- 352 8. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med*
353 2021;27(4):626–31.
- 354 9. Ballering A v, van Zon SKR, olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms
355 after COVID-19 in the Netherlands: an observational cohort study. *The Lancet*
356 2022;400(10350):452–61.
- 357 10. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVID-19
358 Infection. *JAMA Netw Open* 2021;4(2):e210830.
- 359 11. Cutler DM. The Costs of Long COVID. *JAMA Health Forum* 2022;3(5):e221809.
- 360 12. Belluck P. Long Covid Is Keeping Significant Numbers of People Out of Work, Study Finds. *New*
361 *York Times*. 2023;
- 362 13. SHINING A LIGHT ON LONG COVID: An Analysis of Workers' Compensation Data [Internet]. 2023
363 [cited 2023 Jan 29]. Available from: nysif.com
- 364 14. Levine RL. Addressing the Long-term Effects of COVID-19. *JAMA* 2022;
- 365 15. Souden M. Overview of VA Data, Information Systems, National Databases and Research Uses.
366 2017;
- 367 16. Clinical Spectrum of SARS-CoV-2 Infection [Internet]. 2022 [cited 2023 Jan 30]; Available from:
368 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>
- 369 17. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. *New England*
370 *Journal of Medicine* 2016;375(17):1617–27.
- 371 18. Sahni S, Talwar A, Khanijo S, Talwar A. Socioeconomic status and its relationship to chronic
372 respiratory disease. *Adv Respir Med* 2017;85(2):97–108.
- 373 19. Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension. *J Hypertens*
374 2015;33(2):221–9.
- 375 20. Jaffiol C, Thomas F, Bean K, Jégo B, Danchin N. Impact of socioeconomic status on diabetes and
376 cardiovascular risk factors: Results of a large French survey. *Diabetes Metab* 2013;39(1):56–62.
- 377 21. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms.
378 *Eur J Radiol* 2020;127:109009.
- 379 22. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis,
380 and Angiogenesis in Covid-19. *New England Journal of Medicine* 2020;383(2):120–8.

- 381 23. Matheson AM, McIntosh MJ, Kooner HK, et al. Persistent 129Xe MRI Pulmonary and CT Vascular
382 Abnormalities in Symptomatic Individuals with Post-Acute COVID-19 Syndrome. *Radiology* 2022;
- 383 24. Kuehn BM. Cardiac Complications More Common After COVID-19 Than Vaccination. *JAMA*
384 2022;327(20):1951.
- 385 25. Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. *Nat Rev Gastroenterol*
386 *Hepatol* 2022;19(6):345–6.
- 387 26. Costa ÍF, Bonifácio LP, Bellissimo-Rodrigues F, et al. Ocular findings among patients surviving
388 COVID-19. *Sci Rep* 2021;11(1):11085.
- 389 27. What is long COVID? [Internet]. 2022 [cited 2023 Feb 10]; Available from: [https://www.ama-](https://www.ama-assn.org/delivering-care/public-health/what-long-covid)
390 [assn.org/delivering-care/public-health/what-long-covid](https://www.ama-assn.org/delivering-care/public-health/what-long-covid)
- 391 28. National Healthcare Quality and Disparities Report: Chartbook on Healthcare for Veterans
392 [Internet]. Rockville: 2020.
- 393 29. Peltzman T, Rice K, Jones KT, Washington DL, Shiner B. Optimizing Data on Race and Ethnicity for
394 Veterans Affairs Patients. *Mil Med* 2022;187(7–8):e955–62.
- 395 30. World Health Organization. COVID-19 weekly epidemiological update, edition 133, 8 March 2023
396 [Internet]. Geneva: World Health Organization; [cited 2023 May 5]. Available from:
397 <https://apps.who.int/iris/handle/10665/366416>
- 398